[go: up one dir, main page]

FR24C1036I2 - Derives de piperidinyl indole et leur utilisation en tant qu'inhibiteurs de complement factor b - Google Patents

Derives de piperidinyl indole et leur utilisation en tant qu'inhibiteurs de complement factor b

Info

Publication number
FR24C1036I2
FR24C1036I2 FR24C1036C FR24C1036C FR24C1036I2 FR 24C1036 I2 FR24C1036 I2 FR 24C1036I2 FR 24C1036 C FR24C1036 C FR 24C1036C FR 24C1036 C FR24C1036 C FR 24C1036C FR 24C1036 I2 FR24C1036 I2 FR 24C1036I2
Authority
FR
France
Prior art keywords
inhibitors
complement factor
indole derivatives
piperidinyl
piperidinyl indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1036C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51230246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR24C1036I1 publication Critical patent/FR24C1036I1/fr
Application granted granted Critical
Publication of FR24C1036I2 publication Critical patent/FR24C1036I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR24C1036C 2013-07-15 2024-10-01 Derives de piperidinyl indole et leur utilisation en tant qu'inhibiteurs de complement factor b Active FR24C1036I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846355P 2013-07-15 2013-07-15
US201461977028P 2014-04-08 2014-04-08
PCT/US2014/046515 WO2015009616A1 (fr) 2013-07-15 2014-07-14 Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément

Publications (2)

Publication Number Publication Date
FR24C1036I1 FR24C1036I1 (fr) 2024-12-06
FR24C1036I2 true FR24C1036I2 (fr) 2025-08-01

Family

ID=51230246

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1036C Active FR24C1036I2 (fr) 2013-07-15 2024-10-01 Derives de piperidinyl indole et leur utilisation en tant qu'inhibiteurs de complement factor b

Country Status (40)

Country Link
US (2) US9682968B2 (fr)
EP (2) EP3299365A1 (fr)
JP (1) JP6378761B2 (fr)
KR (1) KR102242742B1 (fr)
CN (1) CN105579444B (fr)
AP (1) AP2016008992A0 (fr)
AU (1) AU2014290298B2 (fr)
BR (1) BR112016000909B1 (fr)
CA (1) CA2917839C (fr)
CL (1) CL2016000060A1 (fr)
CU (1) CU24397B1 (fr)
CY (2) CY1119767T1 (fr)
DK (1) DK3022192T3 (fr)
EA (1) EA031030B1 (fr)
ES (1) ES2655855T4 (fr)
FI (1) FIC20240032I1 (fr)
FR (1) FR24C1036I2 (fr)
GT (1) GT201600007A (fr)
HR (1) HRP20172000T1 (fr)
HU (2) HUE037510T2 (fr)
IL (2) IL243540B (fr)
JO (1) JO3425B1 (fr)
LT (2) LT3022192T (fr)
MX (1) MX351291B (fr)
MY (2) MY196427A (fr)
NL (1) NL301292I2 (fr)
NO (1) NO2024042I1 (fr)
PE (1) PE20161066A1 (fr)
PH (1) PH12016500072B1 (fr)
PL (1) PL3022192T3 (fr)
PT (1) PT3022192T (fr)
RS (1) RS56721B1 (fr)
SG (1) SG11201600086PA (fr)
SI (1) SI3022192T1 (fr)
SV (1) SV2016005137A (fr)
TN (1) TN2016000017A1 (fr)
TW (1) TWI641600B (fr)
UA (1) UA117371C2 (fr)
UY (1) UY35663A (fr)
WO (1) WO2015009616A1 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EP3340982B1 (fr) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (fr) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
AU2017290593A1 (en) * 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN113444047B (zh) * 2016-07-20 2023-06-16 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
EP3474820B1 (fr) 2017-08-24 2024-02-07 Novo Nordisk A/S Compositions glp-1 et ses utilisations
ES3022885T3 (en) 2017-08-31 2025-05-29 Novartis Ag Piperidinyl-indole derivatives for use in the treatment of c3 glomerulopathy
KR20210032950A (ko) 2018-07-16 2021-03-25 노파르티스 아게 페닐피페리디닐 인돌 유도체를 제조하기 위한 화학적 방법
WO2020041301A1 (fr) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3856164B1 (fr) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Formes morphiques d'inhibiteurs du facteur d du complément
BR112021013174A2 (pt) 2019-01-11 2021-11-03 Novartis Ag Anticorpos anti-cd40 para uso no tratamento da hidradenite supurativa
EP3908279B1 (fr) 2019-01-11 2024-08-28 Novartis AG Inhibiteur de lta4h destiné au traitement ou à la prévention de l'hidrosadénite suppurée
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
TW202504893A (zh) 2020-05-18 2025-02-01 瑞士商諾華公司 Lnp023之結晶形式
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
WO2022013604A1 (fr) 2020-07-16 2022-01-20 Novartis Ag Méthodes d'utilisation d'inhibiteurs du facteur b
US20230331710A1 (en) 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
IL300432A (en) * 2020-08-07 2023-04-01 Shanghai Meiyue Biotech Dev Co Ltd An inhibitor of complement factor B, and the composition of the drugs, the method of preparation therefor and its use
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
JP7641388B2 (ja) * 2020-12-30 2025-03-06 エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド 一連のピペリジン置換安息香酸系化合物及びその使用
CN119798257A (zh) * 2020-12-30 2025-04-11 江苏恒瑞医药股份有限公司 含氮桥杂环化合物、其制备方法及其在医药上的应用
CA3205097A1 (fr) * 2021-01-14 2022-07-21 Jason Allan Wiles Inhibiteurs macrocycliques du facteur b du complement
CN117062810A (zh) * 2021-04-16 2023-11-14 正大天晴药业集团股份有限公司 一系列双环取代的芳香羧酸类化合物
US20240238266A1 (en) * 2021-05-07 2024-07-18 Novartis Ag Iptacopan for the treatment of atypical hemolytic uremic syndrome
KR20240017004A (ko) * 2021-06-03 2024-02-06 치누크 세라퓨틱스, 인크. 치환된 인돌 화합물 및 이의 사용 방법
JP2024522769A (ja) 2021-06-18 2024-06-21 ノバルティス アーゲー 自己免疫性血液学的疾患を治療する方法
US20240360103A1 (en) * 2021-06-30 2024-10-31 Apellis Pharmaceuticals, Inc. Complement inhibition
US20240383917A1 (en) 2021-08-18 2024-11-21 Xizang Haisco Pharmaceutical Co., Ltd. Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
WO2023037218A1 (fr) 2021-09-07 2023-03-16 Novartis Ag Utilisation d'inhibiteurs du facteur b pour le traitement de la dégénérescence maculaire liée à l'âge
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途
IL314186A (en) 2022-01-24 2024-09-01 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2023143293A1 (fr) 2022-01-26 2023-08-03 上海美悦生物科技发展有限公司 Forme de sel et forme cristalline d'inhibiteur du facteur b du complément, procédé de préparation correspondant et utilisation associée
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
AU2023229221A1 (en) 2022-03-04 2024-08-15 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
US20250223277A1 (en) 2022-04-01 2025-07-10 Novartis Ag Complement factor b inhibitors and uses thereof
CN119698414A (zh) * 2022-06-20 2025-03-25 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (fr) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 Préparation, application et utilisation d'un composé indole
TW202415654A (zh) * 2022-06-30 2024-04-16 大陸商江蘇恒瑞醫藥股份有限公司 含氮橋雜環衍生物的可藥用鹽、晶型及其製備方法
KR20250056970A (ko) * 2022-08-29 2025-04-28 씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드 일련의 질소 함유 가교 헤테로고리 화합물 및 이의 제조방법
WO2024049977A1 (fr) * 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Composés d'indole substitués et leurs procédés d'utilisation
CN119923389A (zh) 2022-09-10 2025-05-02 江苏豪森药业集团有限公司 2-取代哌啶衍生物、其制备方法和医药用途
WO2024099458A1 (fr) * 2022-11-11 2024-05-16 上海医药工业研究院有限公司 Composé d'acide benzoïque substitué par pipéridine, composition pharmaceutique et utilisation associées
CN120187712A (zh) * 2022-11-14 2025-06-20 诺瓦提斯药物公司 补体因子b抑制剂的固体形式
WO2024114677A1 (fr) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 Préparation, application et utilisation de composés benzospiroindole
WO2024141011A1 (fr) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 Inhibiteur du facteur b du complément, composition pharmaceutique et utilisation de celui-ci
WO2024148274A1 (fr) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Inhibition du complément
KR20250145630A (ko) * 2023-02-22 2025-10-13 하이스코 파마수티컬 그룹 컴퍼니 리미티드 벤조 질소 헤테로방향족 고리 유도체의 약학적 조성물 및 의약에서의 이의 응용
IL322259A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of using factor b inhibitors
WO2024193575A1 (fr) * 2023-03-21 2024-09-26 上海美悦生物科技发展有限公司 Composé spiro, composition pharmaceutique associée, son procédé de préparation et son utilisation
WO2024222852A1 (fr) 2023-04-27 2024-10-31 上海翰森生物医药科技有限公司 Sel de composé de pipéridinylindole et son procédé de préparation
WO2025008453A1 (fr) 2023-07-04 2025-01-09 Sitala Bio Ltd Dérivés de 2-(1h-indol-4-yl)méthyl)-isoindoline en tant qu'inhibiteurs de facteur b
WO2025008451A1 (fr) 2023-07-04 2025-01-09 Sitala Bio Ltd Dérivés de 2-(1h-indol-4-yl)méthyl)2h-indazole utilisés en tant qu'inhibiteurs du facteur b
WO2025008517A1 (fr) 2023-07-06 2025-01-09 Sitala Bio Ltd Dérivés d'indole à activité inhibitrice du facteur b
WO2025008516A2 (fr) 2023-07-06 2025-01-09 Sitala Bio Ltd Nouveaux composés
TWI896250B (zh) * 2023-07-26 2025-09-01 大陸商上海美悦生物科技發展有限公司 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途
TW202508580A (zh) 2023-08-25 2025-03-01 瑞士商諾華公司 使用因子b抑制劑之方法
AR133953A1 (es) 2023-09-29 2025-11-19 Novartis Ag Inhibidores del factor b del complemento y usos de los mismos
WO2025083621A1 (fr) 2023-10-20 2025-04-24 Novartis Ag Traitement de l'hidradénite suppurée à l'aide d'anticorps anti-baff-r
WO2025119266A1 (fr) * 2023-12-05 2025-06-12 西藏海思科制药有限公司 Utilisation d'un dérivé de cycle hétéroaromatique azoté benzo dans le traitement d'une maladie induite par le facteur b du complément
WO2025148628A1 (fr) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 Dérivé de pipéridinyl indole, son procédé de préparation et son utilisation
WO2025172535A1 (fr) 2024-02-15 2025-08-21 Sitala Bio Ltd Composés indole et benzimidazole utilisés en tant qu'inhibiteurs du facteur b
TW202533829A (zh) 2024-02-16 2025-09-01 瑞士商諾華公司 用於治療anca相關性血管炎的因子b抑制劑
WO2025185734A1 (fr) * 2024-03-08 2025-09-12 江苏豪森药业集团有限公司 Sel de composé spiro polycyclique et forme cristalline associée, procédé de préparation s'y rapportant et utilisation médicale associée
WO2025237237A1 (fr) * 2024-05-11 2025-11-20 Alebund Pharmaceuticals (Hong Kong) Limited Inhibiteurs du facteur b du complément

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
BR0317548A (pt) 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
US7524878B2 (en) 2003-04-30 2009-04-28 The Institute For Pharmaceuticals Discovery Llc Phenyl substituted carboxylic acids
CA2587566A1 (fr) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Acides carboxyliques a substitution phenyle
WO2006086255A2 (fr) 2005-02-08 2006-08-17 Merck & Co., Inc. Inhibiteurs de kinases de controle
EP2205085A1 (fr) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. Dérivés d'indole 2-aryle ou hétéroaryle
WO2009076404A1 (fr) 2007-12-10 2009-06-18 Epix Delaware, Inc. Composés de carboxyamide et leur utilisation comme antagonistes du récepteur ccr2de la chimiokine
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8877944B2 (en) 2009-07-14 2014-11-04 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2012068589A2 (fr) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
WO2012093101A1 (fr) * 2011-01-04 2012-07-12 Novartis Ag Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
KR20150003903A (ko) * 2012-05-04 2015-01-09 노파르티스 아게 보체 경로 조절제 및 그의 용도
EP2864322B1 (fr) * 2012-06-20 2016-04-27 Novartis AG Modulateur de la voie d'activation du complément et ses utilisations
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Also Published As

Publication number Publication date
US9682968B2 (en) 2017-06-20
RS56721B1 (sr) 2018-03-30
AU2014290298B2 (en) 2017-06-15
IL268623A (en) 2019-10-31
US20180009795A1 (en) 2018-01-11
PL3022192T3 (pl) 2018-03-30
CY2024027I1 (el) 2025-09-26
CN105579444B (zh) 2018-05-01
SI3022192T1 (en) 2018-01-31
JP2016526576A (ja) 2016-09-05
GT201600007A (es) 2018-12-18
LT3022192T (lt) 2017-12-27
PE20161066A1 (es) 2016-10-30
WO2015009616A1 (fr) 2015-01-22
TWI641600B (zh) 2018-11-21
JP6378761B2 (ja) 2018-08-22
NO2024042I1 (no) 2024-09-30
HUE037510T2 (hu) 2018-09-28
SV2016005137A (es) 2018-06-12
HUS2400034I1 (hu) 2024-10-28
BR112016000909B1 (pt) 2023-05-02
SG11201600086PA (en) 2016-02-26
CA2917839C (fr) 2022-05-03
JO3425B1 (ar) 2019-10-20
CY2024027I2 (el) 2025-09-26
IL243540B (en) 2019-09-26
MX351291B (es) 2017-10-09
AU2014290298A1 (en) 2016-02-11
LTPA2024526I1 (fr) 2024-10-10
FIC20240032I1 (fi) 2024-10-01
CL2016000060A1 (es) 2016-06-10
CN105579444A (zh) 2016-05-11
NL301292I2 (nl) 2024-10-30
US10093663B2 (en) 2018-10-09
CU20160006A7 (es) 2016-08-31
DK3022192T3 (en) 2018-01-22
UY35663A (es) 2015-02-27
EA031030B1 (ru) 2018-11-30
MY196427A (en) 2023-04-10
MY187454A (en) 2021-09-22
EP3022192B1 (fr) 2017-10-11
TW201546058A (zh) 2015-12-16
KR102242742B1 (ko) 2021-04-23
FR24C1036I1 (fr) 2024-12-06
CA2917839A1 (fr) 2015-01-22
CY1119767T1 (el) 2018-06-27
IL243540A0 (en) 2016-02-29
EP3299365A1 (fr) 2018-03-28
PT3022192T (pt) 2018-01-15
NZ715780A (en) 2021-03-26
US20160152605A1 (en) 2016-06-02
HK1221217A1 (en) 2017-05-26
AP2016008992A0 (en) 2016-01-31
IL268623B (en) 2020-01-30
BR112016000909A2 (pt) 2017-07-25
TN2016000017A1 (en) 2017-07-05
BR112016000909A8 (pt) 2020-01-07
UA117371C2 (uk) 2018-07-25
EA201690223A1 (ru) 2016-06-30
ES2655855T3 (es) 2018-02-21
HRP20172000T1 (hr) 2018-02-09
ES2655855T4 (es) 2024-09-06
CU24397B1 (es) 2019-04-04
KR20160030556A (ko) 2016-03-18
EP3022192A1 (fr) 2016-05-25
PH12016500072A1 (en) 2016-04-18
PH12016500072B1 (en) 2016-04-18

Similar Documents

Publication Publication Date Title
FR24C1036I2 (fr) Derives de piperidinyl indole et leur utilisation en tant qu'inhibiteurs de complement factor b
IL272377A (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
IL283660A (en) Compositions and methods for modulating apolipoprotein (a) expression
HUE052099T2 (hu) Indol származékok felhasználásra az orvostudományban
HRP20182179T1 (hr) 2,3-disupstituirani 1-acil-4-amino-1,2,3,4-tetrahidrokonolin derivati i njihova uporaba kao inhibitora bromodomena
DK3663292T3 (da) Diphenylmethan-derivat i krystallinsk form
HUE053215T2 (hu) Heterociklusos amidok kináz inhibitorokként
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
ME03336B (fr) Inhibiteurs d'adn-pk
EP2880515A4 (fr) Détection d'interaction
HUE043440T2 (hu) Policiklusos amidszármazékok mint CDK9 inhibitorok
HUE036750T2 (hu) Alfa-v-béta-6 integrin antagonistákként alkalmazható naftiridin-származékok
DK3204359T3 (da) Tetrahydroisoquinolinderivater
ME03485B (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP2970569A4 (fr) Carbènes persistants et compositions associées
CL2014001147S1 (es) Soporte de altavoz
IL243728B (en) rorc2-inhibiting indole derivatives and their uses
EP2952513A4 (fr) Dérivé d'azole et de benzène
DK3371168T3 (da) Indolin-2-on-derivater
HUE046994T2 (hu) Pirido-oxazinon származékok TNAP inhibitorokként
BR112015023621A2 (pt) derivados de menopenem e usos dos mesmos
FI20140206A7 (fi) Puun halkomislaite
FI10001U1 (fi) Puun runkosuoja ja tukijalka puun runkosuojaa varten
TH148816B (th) อนุพันธ์ฟิวส์เอดแอโซล
TH1601000631A (th) อนุพันธ์ไดอะซาคาร์บาโซลในรูป tau-pet-ลิแกนด์